text_1: 患者 既往 接受 过 ≥ 2 种 HER2 靶向 治疗 , 包括 曲妥 珠 单抗 emtansine ( trastuzumab emtansine ) ( T - DM1 ) 和 紫杉醇 .
  
text_2: patients had prior exposure to ≥ 2 HER2 therapies , including trastuzumab emtansine ( T @-@ DM1 ) and a taxane .
  